Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPC-15 melatonin pharmacokinetics in healthy Japanese adults and elderly
jRCT2071220113Phase 1Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of melatonin in Sleep onset insomnia, Mild Cognitive Impairment (MCI) and Dementia (5 arms), sponsored by Nobelpharma Co., Ltd. Primary endpoints: Serum melatonin concentration and Pharmacokinetic parameters. Started Mar 2023; status: completed.
02
Drugs
melatonin
03
Conditions
Sleep onset insomniaMild Cognitive Impairment (MCI)Dementia
Beyond the preview
Go deeper on jRCT2071220113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220113.